PMID- 25484592
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20181113
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 10
DP  - 2014
TI  - Uptitrating amlodipine significantly reduces blood pressure in diabetic patients 
      with hypertension: a retrospective, pooled analysis.
PG  - 651-9
LID - 10.2147/VHRM.S64511 [doi]
AB  - Diabetic patients with hypertension are approximately twice as likely to develop 
      cardiovascular disease as non-diabetic patients with hypertension. Given that 
      hypertension affects  approximately 60% of patients with diabetes, effective blood pressure 
      (BP) management is important in this high-risk population. This post-hoc analysis 
      pooled data from six clinical studies to quantify additional BP efficacy achieved 
      when titrating hypertensive diabetic patients from amlodipine 5 mg to 10 mg. 
      Approximately half of the diabetic patients were male (44/98; 44.9%) with a mean 
      (standard deviation [SD]) age of 60.6 (9.6) years and a baseline mean (standard 
      error [SE]) systolic blood pressure/diastolic blood pressure (SBP/DBP) of 150.8 
      (1.30)/87.5 (0.94) mmHg while on amlodipine 5 mg (159.1 [1.40]/92.6 [0.94] mmHg 
      prior to treatment). In comparison, 350/610 (57.4%) non-diabetic patients were 
      male with a mean (SD) age of 58.7 (11.1) years and baseline mean (SE) SBP/DBP of 
      150.3 (0.62)/90.9 (0.41) mmHg while on amlodipine 5 mg (160.0 [0.67]/96.2 [0.45] 
      mmHg prior to treatment). Increasing amlodipine from 5 mg to 10 mg lowered 
      sitting SBP by -12.5 mmHg (95% confidence interval (CI): -15.5, -9.5; P<0.0001) 
      and DBP by -6.0 mmHg (-7.4, -4.6; P<0.0001) in diabetic patients; and SBP by 
      -12.4 mmHg (-13.5, -11.3; P<0.0001) and DBP by -7.3 mmHg (-8.0, -6.7; P<0.0001) 
      in non-diabetic patients. In total, 12.0% (95% CI: 6.4, 20.0) of diabetic 
      patients achieved their BP goal versus 46.4% (42.4, 50.4) of non-diabetic 
      patients after titration to amlodipine 10 mg. Overall, 22.0% of diabetic patients 
      experienced 31 adverse events (AEs) and 28.9% of non-diabetic patients 
      experienced 282 AEs. Serious AEs were reported by one (1.0%) diabetic and five 
      (0.8%) non-diabetic patients. In this analysis, increasing amlodipine from 5 mg 
      to 10 mg produced a clinically significant reduction in the BP of diabetic 
      hypertensive patients, similar to non-diabetic patients, highlighting the 
      importance of optimizing amlodipine titration in this high-risk population.
FAU - Jeffers, Barrett W
AU  - Jeffers BW
AD  - Pfizer Inc., New York, NY, USA.
FAU - Bhambri, Rahul
AU  - Bhambri R
AD  - Pfizer Inc., New York, NY, USA.
FAU - Robbins, Jeffery
AU  - Robbins J
AD  - Pfizer Inc., New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20141114
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 1J444QC288 (Amlodipine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amlodipine/*administration & dosage/adverse effects
MH  - Antihypertensive Agents/*administration & dosage/adverse effects
MH  - Blood Pressure/*drug effects
MH  - Calcium Channel Blockers/*administration & dosage/adverse effects
MH  - Comorbidity
MH  - Diabetes Mellitus/diagnosis/*epidemiology
MH  - Drug Dosage Calculations
MH  - Female
MH  - Humans
MH  - Hypertension/diagnosis/*drug therapy/epidemiology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC4240189
OTO - NOTNLM
OT  - calcium channel blockers
OT  - cardiovascular disease prevention
OT  - diabetes
OT  - efficacy
OT  - hypertension
EDAT- 2014/12/09 06:00
MHDA- 2015/04/07 06:00
PMCR- 2014/11/14
CRDT- 2014/12/09 06:00
PHST- 2014/12/09 06:00 [entrez]
PHST- 2014/12/09 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
PHST- 2014/11/14 00:00 [pmc-release]
AID - vhrm-10-651 [pii]
AID - 10.2147/VHRM.S64511 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2014 Nov 14;10:651-9. doi: 10.2147/VHRM.S64511. 
      eCollection 2014.